Research To Practice | Oncology Videos

Latest Episodes:

ER-Positive Metastatic Breast Cancer | 5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer Mar 21, 2025

Show notes

Featuring an interview with Dr Komal Jhaveri, including the following topics:

Emerging treatment options for advanced ER-positive breast cancer (0:00)
- Burstein H. Emerging treatment options for advanced ER+ breast cancer. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01 Discussant.
Elacestrant real-world progression-free survival for adult patients with ER-positive, HER2-negative advanced breast cancer: A retrospective analysis using insurance claims in the United States (7:28)
- Swallow E et al. Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: A retrospective analysis using insurance claims in the United States. San Antonio Breast Cancer Symposium 2024;Abstract P3-10-08.
Ongoing clinical trials involving oral SERDs (9:03)
- Kaklamani V et al. ELCIN: Elacestrant in women and men with CDK4/6 inhibitor (CDK4/6i)-naïve estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (mBC): An open-label multicenter phase 2 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-20.
- An adjuvant endocrine-based therapy study of camizestrant (AZD9833) in ER+/HER2- early breast cancer (CAMBRIA-2). NCT05952557
- Bardia A et al. ELEGANT: Elacestrant versus standard endocrine therapy in women & men with node-positive, estrogen receptor-positive, HER2-negative, early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study. San Antonio Breast Cancer Symposium 2024;Abstract P2-08-21.
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:48)
- Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract

CME information and select publications

Oncology Nursing Update: Bispecific Antibodies in Lymphoma Part 1 — An Interview with Ms Robin Klebig Mar 18, 2025

Show notes

Featuring an interview with Ms Robin Klebig, including the following topics:

Overview of the natural history and treatment landscapes of lymphoma subtypes (0:00)
Structure and mechanisms of action of bispecific antibodies (23:41)
Similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (28:14)
Case: A man in his early 50s with multiagent/multiregimen-refractory follicular lymphoma who experienced disease progression with chimeric antigen receptor T-cell therapy now receives mosunetuzumab (39:14)
Case: A woman in her mid 60s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives glofitamab (49:08)
Case: A man in his mid 60s with R/R high-grade B-cell lymphoma with MYC and Bcl-2 rearrangements receives epcoritamab (52:57)
Case: A man in his early 60s with composite lymphoma receives epcoritamab (56:55)

NCPD information and select publications

Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Mar 15, 2025

Show notes

Featuring perspectives from Dr Thomas E Hutson, Dr Rana R McKay, Dr Sumanta Kumar Pal and Dr Tian Zhang, moderated by Dr Pal, including the following topics:

Introduction (0:00)
Immunotherapeutic Strategies for Localized and Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Dr Hutson (2:34)
Optimal Management of Relapsed/Refractory RCC — Dr Zhang (32:49)
Role of HIF-2α Inhibitors in the Treatment of Sporadic and von Hippel-Lindau-Associated RCC — Dr McKay (1:04:02)
Current and Future Care of Patients with Non-Clear Cell RCC — Dr Pal (1:33:13)

CME information and select publications

Colorectal Cancer — Year in Review Series on Relevant New Datasets and Advances Mar 14, 2025

Show notes

Featuring perspectives from Dr Scott Kopetz and Dr Jeffrey Meyerhardt, including the following topics:

Introduction (0:00)
Cell-Free DNA Molecular Residual Disease Assays in Clinical Practice (3:25)
Immunotherapy for Localized and Metastatic Microsatellite Instability-High Colorectal Cancer (28:27)
Other Important Datasets (46:06)

CME information and select publications

Colorectal Cancer | Scott Kopetz, MD, PhD Mar 13, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Advances in the Management of Metastatic CRC (mCRC) — Scott Kopetz, MD, PhD

CME information and select publications

Colorectal Cancer | Jeffrey Meyerhardt, MD, MPH Mar 12, 2025

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 1: Optimizing the Care of Patients with Localized Colorectal Cancer (CRC) — Jeffrey Meyerhardt, MD, MPH

CME information and select publications

Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management Mar 11, 2025

Show notes

Featuring perspectives from Dr Kevin S Hughes and Dr Mark Robson, including the following topics:

Introduction (0:00)
Optimal Approach to Genetic Testing for Patients with Localized Breast Cancer (BC) — Dr Hughes (10:22)
Available Data with and Practical Application of PARP Inhibition as Adjuvant Therapy for Patients with BC — Dr Robson (38:06)

CME information and select publications

Urothelial Bladder Cancer and Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Mar 07, 2025

Show notes

Featuring perspectives from Dr Terence Friedlander and Dr Matthew D Galsky, Dr Neeraj Agarwal and Dr Andrew J Armstrong, moderated by Dr Elisabeth I Heath, including the following topics:

Introduction (0:00)
Role of Antibody-Drug Conjugates (ADCs) in Front-Line Therapy for Metastatic Urothelial Bladder Cancer (mUBC) — Dr Friedlander (2:53)
Evidence-Based Use of ADCs for Relapsed/Refractory mUBC — Dr Galsky (33:04)
Evolving Role of Treatment Intensification with Androgen Receptor Pathway Inhibitors for Nonmetastatic and Metastatic Prostate Cancer — Dr Armstrong (1:01:28)
Optimal Integration of PARP Inhibitors into Therapy for Prostate Cancer — Dr Agarwal (1:27:49)

CME information and select publications

5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer Mar 03, 2025

Show notes

Featuring an interview with Dr Komal Jhaveri, including the following topics:

Imlunestrant, an oral selective estrogen receptor degrader (SERD), with and without abemaciclib for ER-positive, HER2-negative advanced or metastatic breast cancer (0:00)
- Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01.
- Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2024;[Online ahead of print]. Abstract
- Rugo HS et al. Elacestrant abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2024; Abstract PS7-07.
Elacestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1-mutated tumors: Subgroup analyses from the Phase III EMERALD trial by duration of prior endocrine therapy with a CDK4/6 inhibitor and in clinical subgroups (7:40)
- Bardia A et al. Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res 2024;30(19):4299-309. Abstract
Pharmacokinetics and safety of imlunestrant in patients with hepatic impairment (11:25)
- Wang XA et al. Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment. San Antonio Breast Cancer Symposium 2024;Abstract P4-10-07.
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:15)
- Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract